ACT (Accelerated Clinical Trials)
AI-powered platform to accelerate end-to-end clinical trial processes
Platform · Cloud SaaSCompany source
Company profile
About ConcertAI
ConcertAI is a healthcare AI company that orchestrates clinical expertise, real-world data, and applied artificial intelligence to deliver practical intelligence for oncology and other complex diseases. The company operates across the healthcare ecosystem, serving life sciences and pharmaceutical companies, healthcare systems, oncology practices, and enterprise imaging departments. ConcertAI's platform integrates over 13 million de-identified patient records through its CancerLinQ network, providing comprehensive coverage for both solid and hematologic cancers with weekly data updates. The company's solutions span four primary areas: Real-World Evidence (Precision360, Precision Explorer, Translational360, Patient360), Clinical Trials (ACT, TriaLinQ), Commercial Intelligence (Cadence Suite, Data Foundry, Precision GTM), and Enterprise Imaging through its TeraRecon division (Advanced Visualization, Imaging Workflows, DETECT, AI Framework). ConcertAI's AI-driven approach has been used in over 500 peer-reviewed publications and is built by a team of hundreds of advanced degree-holders and data scientists. The company works with 75% of the top 30 life sciences companies and approximately 50% of the top 250 global healthcare systems. ConcertAI's technology partners include NVIDIA and AWS, while laboratory partnerships include Caris, Guardant, Foundation Medicine, and NeoGenomics. The company's mission centers on supporting high-stakes decisions in tight timelines, from research to treatment to delivery, helping organizations move from fragmented data to confident decisions that advance care in complex diseases.
Company description ConcertAI official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at ConcertAI?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- complex diseases
- hematologic cancers
- oncology
- solid tumors
Who it serves
- CROs
- Health Systems
- Life Sciences
- Oncology Practices
- Pharma
Deployment & integration
Cloud Saas · On Premise · Other deployment with recorded integration context.
Geographic context
MarketsGlobal · United States
Company sourceOfficial website
Company milestones
Platform expansion
CancerLinQ suite expanded with AI-driven trial matching. CancerLinQ network announced expansion to new clinical sites. ConcertAI announced Cadence Suite for full visibility into patient treatment journey.
Partnerships
Recorded partners
- AWS
- Caris
- Foundation Medicine
- Guardant
- NeoGenomics
- NVIDIA
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Cadence Suite
Full visibility into the patient treatment journey
Platform · Cloud SaaSCompany source
CancerLinQ Suite
AI-driven oncology intelligence for point-of-care decisions
Platform · Cloud SaaSCompany source
Data Foundry Precision360
Commercial data infrastructure for oncology insights
Platform · Cloud SaaSCompany source
Patient360
Comprehensive patient-level insights for oncology
Platform · Cloud SaaSCompany source
Precision Explorer
Real-world evidence exploration and analysis tool
Software · Cloud SaaSCompany source
Precision GTM
Go-to-market intelligence for life sciences
Platform · Cloud SaaSCompany source
Precision360
AI-curated real-world evidence dataset for oncology research
Platform · Cloud SaaSCompany source
Scientific Services
Expert scientific consulting for real-world evidence studies
Service · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Validation of an all-source composite mortality endpoint in the US population.Journal of comparative effectiveness research · Aug 31, 2026
Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States.Urologic oncology · Jul 10, 2026
Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative.Clinical pharmacology and therapeutics · Jun 4, 2026
Emulating Comparative Oncology Trials With Real-World Evidence Studies (ENCORE): Process Development and Methodological Considerations for Oncology Real-World Data.Clinical pharmacology and therapeutics · Apr 1, 2026
Harmonizing Logical Observation Identifiers Names and Codes (LOINC) Codes and Units in Real-World Oncology Data: Method Development and Evaluation.JMIR medical informatics · Mar 9, 2026
Trifluridine-Tipiracil with and without Bevacizumab in Colorectal Cancer.NEJM evidence · Mar 1, 2026
Clinical validation
Clinical-trial records
A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast CancerNCT06686602 · Mentioned · COMPLETED
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of TreatmentNCT06557967 · Mentioned · COMPLETED
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast CancerNCT06040593 · Mentioned · COMPLETED
Axitinib Therapy Management StudyNCT04555603 · Mentioned · WITHDRAWN
A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of TherapyNCT05853432 · Mentioned · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
50% reduction in trial amendments
through AI-driven design validation and predictive modeling
3X boost in patient recruitment
using AI-powered site selection and real-time data
10-20 months reduction in trial timelines
through optimized study design, recruitment, and site activation
Millions in cost savings
by minimizing costly amendments and streamlining processes
Clinical Trial Sponsors
Trial timeline reduction
10-20 months reduction in trial completion timelines through automated workflows
Leading Life Sciences Companies
Clinical trial optimization and acceleration
50% reduction in trial amendments through AI-driven design validation
Pharmaceutical Sponsors and CROs
Patient recruitment acceleration
3X boost in patient recruitment using AI-powered site selection and real-time data
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from ConcertAI
Recent articles published on ConcertAI's official website.
From Orchestration to Discovery: ConcertAI, NVIDIA, and What Comes Next with BioNeMo
Read on ConcertAIBuilding the Trustworthy Data Foundation for Healthcare AI
Read on ConcertAIPrecision360’s weekly curation powers new possibility
Read on ConcertAIAI In Clinical Trials: From Promise To Measurable Impact
Read on ConcertAITranslational360 for Decision-Ready Evidence | ConcertAI
Read on ConcertAI07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.